tbuckley/cabot-search huggingface dataset:
Assessing the Bleeding Risk after Liver Biopsy Using New Clinical and Biological Tools: A Prospective Analysis of 162 Procedures
Authors: J. Bissonnette, E. de Raucourt, E. Gigante, L. Boudaoud, F. Durand, D. Valla, V. Vilgrain, P.-E. Rautou
Journal: Journal of Hepatology (2016)
Killer cell immunoglobulin-like receptors are associated with common variable immune deficiency pathogenesis
Authors: Yuge Wang, Tracy Hwangpo, Maureen P. Martin, Nicolas Vince, Ying Qi, Richard J. Reynolds, Devin Absher, Xiaojiang Gao, Carol A. Ballinger, Peter D. Burrows, T. Prescott Atkinson, Elizabeth E. Brown, Ada Elgavish, Cunren Liu, Mary Carrington, Harry W. Schroeder
Journal: Journal of Allergy and Clinical Immunology (2016)
Disorders related to sexuality and gender identity in the ICD‐11: revising the ICD‐10 classification based on current scientific evidence, best clinical practices, and human rights considerations
Authors: Geoffrey M. Reed, Jack Drescher, Richard B. Krueger, Elham Atalla, Susan D. Cochran, Michael B. First, Peggy T. Cohen‐Kettenis, Iván Arango‐de Montis, Sharon J. Parish, Sara Cottler, Peer Briken, Shekhar Saxena
Journal: World Psychiatry (2016)

In the World Health Organization's forthcoming eleventh revision of the International Classification of Diseases and Related Health Problems (ICD-11), substantial changes have been proposed to the ICD-10 classification of mental and behavioural disorders related to sexuality and gender identity. These concern the following ICD-10 disorder groupings: F52 Sexual dysfunctions, not caused by organic disorder or disease; F64 Gender identity disorders; F65 Disorders of sexual preference; and F66 Psychological and behavioural disorders associated with sexual development and orientation. Changes have been proposed based on advances in research and clinical practice, and major shifts in social attitudes and in relevant policies, laws, and human rights standards. This paper describes the main recommended changes, the rationale and evidence considered, and important differences from the DSM-5. An integrated classification of sexual dysfunctions has been proposed for a new chapter on Conditions Related to Sexual Health, overcoming the mind/body separation that is inherent in ICD-10. Gender identity disorders in ICD-10 have been reconceptualized as Gender incongruence, and also proposed to be moved to the new chapter on sexual health. The proposed classification of Paraphilic disorders distinguishes between conditions that are relevant to public health and clinical psychopathology and those that merely reflect private behaviour. ICD-10 categories related to sexual orientation have been recommended for deletion from the ICD-11.
IKKALPHA/Beta Regulate Hepatocarcinogenesis and Biliary Homeostasis by Controlling RIPK1 Activity
Authors: C. Koppe, F. Reisinger, P. Verheugd, J. Gautheron, C. Roderburg, F. Tacke, C. Preisinger, B. Lüscher, M. Vucur, C. Trautwein, M. Heikenwälder, T. Luedde
Journal: Journal of Hepatology (2016)
Intensive lowering of systolic BP did not reduce death or disability more than standard lowering in ICH
Authors: Graeme J. Hankey
Journal: Annals of Internal Medicine (2016)

Source Citation Qureshi AI, Palesch YY, Barsan WG, et al; ATACH-2 Trial Investigators, Neurological Emergency Treatment Trials Network. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016 Jun 8. [Epub ahead of print]. 27276234
Noradrenaline Potentiates Portal Hypertension through the Alpha 2a Adrenergic Receptor – A target for Therapy in Portal Hypertension
Authors: H. Jones, V. Sharma, A.F. Brandao da Silva, N.A. Davies, J. Macnaughtan, R. Jalan, R.P. Mookerjee
Journal: Journal of Hepatology (2016)
Aquaporin-2 in Cirrhosis: Relation to Disease Severity, Markers of Renal Function and Impact on Development of Renal Insufficiency and Mortality
Authors: T.M. Busk, S. Møller, E. Pedersen, A. Gerbes, A. Krag, M. Peck-Radosavljevic, S. Frankova, M.J. Coenraad, F. Bendtsen
Journal: Journal of Hepatology (2016)
Repeated transarterial chemoperfusion and -embolization (TACE) in primary hepatic cholangiocarcinoma (CCC): Local tumor control and survival rate
Authors: T. J. Vogl, N. Naguib, S. Zangos, K. Eichler, T. Gruber
Journal: Journal of Clinical Oncology (2009)

e15595 Background: To evaluate local tumor control and survival data in the palliative and symptomatic treatment of hepatic cholangiocarcinoma (CCC) using repeated transarterial chemoperfusion and -embolization (TACE) with two different chemotherapy protocols. Methods: 41 patients with primary cholangiocarcinoma (CCC) were repeatedly treated with transarterial chemoembolization (TACE) in 4-week intervals. In total, 291 TACE sessions were performed with a mean of 7.1 sessions per patient (mean age: 57.1 years; range, 37–80 years). 22 patients had multiple tumors, 6 showed 1 lesion, 5 had 2 lesions and 8 presented 3 to 4 lesions. The local chemotherapy protocol consisted of Mitomycin C alone (n=20), or in combination with gemcitabine (n=18). Embolization was performed with lipiodol and starch microspheres for vessel occlusion. Tumor response was evaluated by magnetic resonance imaging (MRI) in 3-month intervals. Results: Evaluation of local tumor control according to the RECIST criteria was as follows: partial response 9.8%, stable disease 43.6%, and progressive disease 46.6%. The 1-year survival rate after TACE was 58%, the 2-year survival rate was 21%. The mean survival time from the date of diagnosis of liver involvement was 34.1 months (according to Kaplan-Meier), after first TACE treatment 16.7 months. The median survival time of the palliative group was 14.5 months and of the symptomatic group 6 months. Conclusions: Our data indicated that repeated TACE using the protocols is well tolerated and yields respectable results in patients with unresectable liver lesions from CCC. No significant financial relationships to disclose.
Circulating Neutrophils – Immunological Drivers of Hepatocellular Carcinoma Progression?
Authors: C.E. Willoughby, L.F. Ogle, S.L. Chan, C. Chan, A.K.C. Chan, T.J.S. Cross, W.Y. Ding, D. Jamieson, H.L. Reeves
Journal: Journal of Hepatology (2016)
Clinical Significance of MYD88 Mutation in Patients with Diffuse Large Cell Lymphoma
Authors: Ritsuko Seki, Takashi Okamura, Koteda Satoko, Kuniki Kawaguchi, Kei Noumura, Takayuki Nakamura, Harumi Takeda, Satoshi Morishige, Fumihiko Mouri, Koichi Osaki, Ohshima Koichi, Koji Nagafuji
Journal: Blood (2015)
Establishing the Edinburgh Model: Dose to Injury Response in a Large Animal Infusion Model of Paracetamol-Induced Acute Liver Failure
Authors: P. Treskes, G. Bradbury, B. Vliegenthart, M. Van Wenum, K. Borland, B. Few, A. Hay, P. Hayes, M. Eddleston, E. Clutton, J. Plevris
Journal: Journal of Hepatology (2016)
Insufficient reduction in heart rate during hospitalization despite beta‐blocker treatment in acute decompensated heart failure: insights from the <scp>ASCEND‐HF</scp> trial
Authors: Takeshi Kitai, Justin L. Grodin, Robert J. Mentz, Adrian F. Hernandez, Javed Butler, Marco Metra, John J. McMurray, Paul W. Armstrong, Randall C. Starling, Christopher M. O'Connor, Karl Swedberg, W.H. Wilson Tang
Journal: European Journal of Heart Failure (2016)
Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment
Authors: Johan Maertens, Michael Lübbert, Walter Fiedler, Loic Fouillard, Alf Haaland, Joseph M. Brandwein, Stéphane Lepretre, Oumédaly Reman, Pascal Turlure, Gesine Bug, Carsten Müller-Tidow, Alwin Krämer, Florian Voss, Tillmann Taube, Holger Fritsch, Hartmut Döhner
Journal: Blood (2012)
Inconsistencies among lists of cautioned/prohibited drugs in oncology phase I and phase II trials.
Authors: E. X. Chen, G. R. Pond, L. L. Siu, R. A. Cheiken, J. Nagai, B. You
Journal: Journal of Clinical Oncology (2010)

e13084 Background: The potential for drug-drug interaction is a significant concern for early-phase clinical trials. It is common to include lists of cautioned/prohibited (c/p) drugs in protocols of phase I and II trials. Patient eligibility is affected by these lists. Methods: We reviewed protocols of 100 phase I-II trials conducted at our center between 2004 and 2009. All c/p drugs were collected and compared among trials. In addition, these drugs were checked against the original references cited in each protocol. Results: Among 100 protocols, 77 included lists of c/p drugs to prevent CYP3A4; 2C9 and 2C19-related interactions (65 trials involving 17 investigators and 38 unique study drugs) and/or QTc interval elongation (20 trials involving 8 investigators and 12 unique study drugs). The 65 trials with CYP-related c/p drug lists included 0 to 137 CYP3A4 inhibitors (c:0-137; p:0-134), 0 to 20 inducers (c:0-17; p:0-17) and 10 to 157 CYP3A4 substrates (c:10-157; p:0-10). Even among trials with the same study drug, there is a high degree of inconsistency. Among 9 trials of a tyrosine kinase inhibitor, the numbers of c and p drugs ranged from 0 to 141 and from 1 to 23 respectively. Protocols from the same company, cooperative group, or investigator often include different lists of c/p drugs. These inconsistencies could not be explained by the year of trial activation, type of trial, natures of sponsorship (industry vs. academic), effect of the study drug on CYP, or even by the original reference(s) cited in protocols. Three main references were quoted in 45% protocols. There were discordances among drug lists reported in these references and between protocol lists and reference lists. Similar inconsistency was found for lists of c/p CYP2C9 and 2C19 metabolizing drugs. About 20% protocols included misspellings or confusing drug names. The 20 trials with QTc-interval related drugs listed 11 to 88 drugs (c:0-62: p:11-87). Conclusions: High rates of inconsistencies were found among lists of c/p drugs included in protocols of oncology phase I-II trials. Standardization of c/p drug lists for trial use is warranted. No significant financial relationships to disclose.
Low Sustained Virologic Response (SVR) Rates in Genotype (GT) 2 and 3 Patients with Quantifiable Hepatitis C Virus (HCV) at Week 4 of Treatment with Sofosbuvir (SOF) Containing Regimens
Authors: K. Thornton, P. Deming, M. Sedillo, C. Qualls, T. Box, J. Scott, P. Cox, J. Mera, A. Miller, R. Manch, A. Kohli, R. Gish, A. Moore, N. Sussman, S. Khaderi, S. Arora
Journal: Journal of Hepatology (2016)
Interferon-Stimulated Gene 15 in HBV Infection and Progression of HBV-Related Liver Diseases
Authors: T.V. Hoang, N.X. Hoan, D.P. Giang, N.L. Toan, L.H. Song, C.-T. Bock, P. Kremsner, T. Velavan
Journal: Journal of Hepatology (2016)
Impact of care at NCI-designated Comprehensive Cancer Centers (NCICCCs) on racial differences in prostate cancer-specific survival.
Authors: C. Sun, S. Kurian, G. T. Washington, K. Nielsen-Menicucci, L. E. Crocitto, T. G. Wilson, L. Laddaran, W. Landier, S. Smith, S. Bhatia
Journal: Journal of Clinical Oncology (2010)

6022 Background: Racial differences in prostate cancer-specific survival account for 50% of observed disparities in cancer survival between Caucasians and African Americans. These differences could be due to sociodemographics, disease characteristics, or disease management. NCI confers a “comprehensive” designation to cancer centers, if they demonstrate excellence in research and patient care. Racial differences in receiving care at NCICCCs could possibly contribute to disparity in survival. Methods: Using data from Los Angeles Cancer Surveillance Program, we examined underlying causes of racial differences in prostate-specific survival in 65,203 men (African Americans: 11,842; Caucasians: 53,361) diagnosed with prostate cancer between 1976 and 2003, and followed until 2008. Three NCICCCs serve this area: USC-Norris, UCLA- Jonsson, and City of Hope. Results: Data were examined overall, and for 3 eras: 1976-1987, 1988-1997, and 1998-2003. Overall, African Americans were significantly (p < 0.001) more likely to have low socioeconomic status (33% vs. 6%); no insurance (4% vs. 1%); distant disease (13% vs. 9%); and be managed with “watchful waiting” (23% vs. 15%). Univariately, 5-yr prostate-specific survival was significantly (p < 0.001) inferior for African Americans (86% vs. 89%) and for patients treated at non-NCICCCs (88% vs. 96%), irrespetive of race. After adjustment for sociodemographics, race, insurance, clinical factors, and treatment, care at NCICCC was associated with lower prostate-specific mortality for the 3 eras (HR = 0.81, 0.66, 0.59, p < 0.01). African Americans were less likely to utilize NCICCCs (OR = 1.46, 2.34, 2.50, for 3 eras). Finally, adjustment for treatment at NCICCCs abrogated racial difference in prostate-specific mortality (HR = 1.05, p = 0.5) in the most recent era. Conclusions: Treatment at NCICCCs is associated with > 40% reduction in prostate-specific mortality. African Americans are less likely to utilize NCICCCs for prostate cancer. African Americans and Caucasians have comparable prostate-specific survival if they receive care at NCICCCs. We are currently conducting studies to understand barriers to utilization of NCICCCs. No significant financial relationships to disclose.
Biochemical surrogate markers of hemolysis do not correlate with directly measured erythrocyte survival in sickle cell anemia
Authors: Charles T. Quinn, Eric P. Smith, Shahriar Arbabi, Paramjit K. Khera, Christopher J. Lindsell, Omar Niss, Clinton H. Joiner, Robert S. Franco, Robert M. Cohen
Journal: American Journal of Hematology (2016)

Hemolysis is a key feature of sickle cell anemia (HbSS). Direct quantitation of hemolysis could be used as an objective outcome in clinical trials of new therapeutics for HbSS and would also enable better human studies of the pathogenesis of complications of HbSS that are ostensibly hemolysis‐related, such as pulmonary hypertension. However, contemporary human studies in HbSS have used only surrogate markers of hemolysis rather than direct measurements of RBC survival. We directly quantified hemolysis in HbSS by measuring survival of an age cohort of RBCs labeled with a stable isotope, administered orally as 15 N‐glycine, a metabolic precursor of heme. The atomic excess of 15 N in heme extracted from blood was monitored by mass spectrometry over time. We performed 13 labeling experiments in 11 individuals with HbSS. Mean RBC survival was 31.9 days (range 14.1–53.6). Both HbF level, a known determinant of hemolysis, and absolute reticulocyte count (ARC), an index of the marrow's response to hemolysis, correlated with directly measured RBC survival ( r = 0.61, P &lt; 0.002; r = −0.84, P &lt; 0.001). However, commonly used biochemical surrogates of hemolysis (LDH, AST, bilirubin, and plasma free hemoglobin) did not correlate with directly measured RBC survival. These biochemical surrogates should be interpreted cautiously, at best, in clinical trials and human physiologic studies in HbSS. ARC was the best correlate of total hemolysis, but only 70% of the variation in RBC survival was reflected in this marker. If greater accuracy is required in human studies, 15 N‐glycine RBC labeling can directly and accurately quantify hemolysis. Am. J. Hematol. 91:1195–1201, 2016. © 2016 Wiley Periodicals, Inc.
Intracoronary mesenchymal stem cell or endothelial progenitor cell transfer post myocardial infarction prevents negative remodeling but fails to enhance global functional recovery
Authors: CL Dubois, Daisy Thijs, Glenn Marsboom, H Depelteau, Xiaoshun Liu, W Streb, L Chaothawee, Frederik Maes, M Swinnen, Hilde Gillijns, Marijke Pellens, Desire Collen, Frans Van de Werf, Stefan Janssens
Journal: Journal of the American College of Cardiology (2006)
Safety and Efficacy of IFN- Free Antiviral Therapies in Advanced HCV- Associated Liver Cirrhosis: Results from the German Hepatitis C-Registry (DHC-R)
Authors: K. Deterding, P. Buggisch, H. Klinker, K.-G. Simon, K.H.W. Böker, E. Schott, T. Zimmermann, M. Cornberg, R. Günther, H. Pfeiffer-Vornkahl, C. Sarrazin, M.P. Manns, D. Hüppe, H. Wedemeyer, T. Berg
Journal: Journal of Hepatology (2016)
Structural Basis for Regulation of GPR56/ADGRG1 by Its Alternatively Spliced Extracellular Domains
Authors: Gabriel S. Salzman, Sarah D. Ackerman, Chen Ding, Akiko Koide, Katherine Leon, Rong Luo, Hannah M. Stoveken, Celia G. Fernandez, Gregory G. Tall, Xianhua Piao, Kelly R. Monk, Shohei Koide, Demet Araç
Journal: Neuron (2016)
Novel Serum Lipidomic Signature Correlates with the Grade of Steatosis Measured Biochemically and by Magnetic Resonance Imaging
Authors: R. Jimenez-Agüero, L. Bujanda, E. Arretxe, D. Balgoma, M.J. Perugorria, C. Alonso, E. Eizaguirre, M. Krawczyk, F. Lammert, A. Castro, J.M. Banales
Journal: Journal of Hepatology (2016)
CO-Culture with Mesenchymal Cells Modulates TGF-Beta/Smad And Mapk Pathways in T Regulatory Cells
Authors: Mauro Di Ianni, Beatrice Del Papa, Lorenzo Moretti, Simonetta Piattoni, Debora Cecchini, Elisabetta Bonifacio, Franca Falzetti, Antonio Tabilio
Journal: Blood (2008)
Polycyclic Eruption of the Thighs
Authors: Julia Wu, Rebecca Baxt, Mark Jacobson
Journal: JAMA Dermatology (2016)

A young woman had a painful erythematous eruption over her thighs that was worse during winter but no other symptoms; she was a nonsmoker, took no medications, and worked at a horse stable and rode for many hours a day. What is your diagnosis?
Sequential Therapy with Allogeneic Transplant Followed by Low-Dose Azacitidine for CML Patients That Failed Multiple Tyrosine Kinase Inhibitors
Authors: Marcos De Lima, Sairah Ahmed, Elizabeth J Shpall, Gabriela Rondon, Julienne Chen, Glenda G Woodworth, Alexandre Chiattone, Diem Thuy Chu, Uday R Popat, Susanna R Campos, Amin M Alousi, Chitra M Hosing, Simrit Parmar, Partow Kebriaei, Issa F. Khouri, Jorge E. Cortes, Jean-Pierre J Issa, Richard Champlin
Journal: Blood (2011)
Loss Of p53 Promotes Transformation Of Oncogenic Nras-Induced Chronic Myelomonocytic Leukemia To An Acute Phase
Authors: Jingfang Zhang, Yangang Liu, Guangyao Kong, Yuan-I Chang, Erik A. Ranheim, Jinyong Wang, Juan Du, Alisa Damnernsawad, Jing Zhang
Journal: Blood (2013)
Whole Genome Bisulfite Sequencing of Purified Mouse Promyelocytes Reveals Differentially Methylated Regions in Cells Expressing PML-Rara
Authors: Shamika Ketkar-Kulkarni, Christopher B Cole, David H. Spencer, Angela M. Verdoni, Nichole Havey, Tamara Lamprecht, Vincent Magrini, Ryan T Demeter, Richard K. Wilson, Timothy J Ley
Journal: Blood (2014)
KRAS mutations and outcomes for patients with stage IV NSCLC treated with frontline platinum/pemetrexed based chemotherapy.
Authors: Benjamin Levy, Nagashree Seetharamu, Stacie Richardson, Daniel Jacob Becker, Walter Choi, Andrew Evans, Faiz Y. Bhora, Cliff P. Connery, Michael L. Grossbard, Abraham Chachoua
Journal: Journal of Clinical Oncology (2012)

e18139 Background: KRAS mutations are the most common driver mutation indentified in NSCLC, occurring in 20 - 30% of adenocarcinomas. While several studies suggest KRAS predicts for lack of response to TKI therapy, few data exist regarding its association with outcomes for patients treated with cytotoxic chemotherapy. This study explores the association between KRAS mutations and outcomes (RR, PFS) in a cohort of patients treated with frontline platinum/pemetrexed (PPm) based therapy. Methods: In this retrospective chart review, we evaluated RR and PFS for 16 KRAS + EGFR – pts treated with carboplatin (AUC 5-6) or Cisplatin 75mg/m2 and (Pm)pemetrexed (500 mg/m2) +/- (B)bevacizumab 15mg/kg. For comparators, we identified 19 KRAS - EGFR - patients treated with the same regimen. Maintenance therapy with Pm or Pm+B was given at the discretion of the treating physician. KRAS and EGFR mutational status were assessed by RT-PCR on tumor tissue collected at first diagnosis. RR was assessed using RECIST criteria. Kaplan-Meier estimates for PFS were evaluating using log rank test. Fisher exact test was used to assess the association between KRAS mutation status and response rate. Results: The groups were similar in age (KRAS + mean 61 vs. 60; p=0.87), gender (62% vs. 57% F; p= 0.9), ECOG 2 (0 vs. 10%,p=0.47), smoking hx (93% vs. 94% current/former smokers, p=0.7), brain mets (0% vs. 18% p=0.22), mean number induction cycles (4 in each, p=0.6), cisplatin and bevacizumab use (12% vs 10%, p &gt; 0.1;10% vs. 40%, p=0.10). Pm maintenance was used in 31% KRAS+ (5/16) and 26% KRAS-(5/19) (p=0.79). P+B maintenance was used in 12% (2/16) and 5% (1/19) (p=0.70). RR was 56% in the KRAS + (9/16) vs. 36% KRAS- (7/19) respectively (p=0.3). There was a statistically significant improvement in PFS in the KRAS + group (10.3 mos vs. 5.7 mos, p =0.03). Conclusions: In this small retrospective review, KRAS mutations appeared to be associated with a non-significant improvement in RR and significant improvement in PFS for patients treated with frontline PPm based therapy. Future prospective studies should investigate and validate the predictive value of KRAS for this cytotoxic regimen. [Table: see text]
P0039 : Prediction of HCC recurrence after liver transplantation based on explants pathology: Comparison of prediction accuracy of 4 prognostic models in a prospective external cohort
Authors: C.E. Costentin, F. Roudot-Thoroval, T. Decaens, J. Calderaro, A. Luciani, G. Amaddeo, A. Laurent, C. Duvoux
Journal: Journal of Hepatology (2015)
Suppressors of Superoxide-H 2 O 2 Production at Site I Q of Mitochondrial Complex I Protect against Stem Cell Hyperplasia and Ischemia-Reperfusion Injury
Authors: Martin D. Brand, Renata L.S. Goncalves, Adam L. Orr, Leonardo Vargas, Akos A. Gerencser, Martin Borch Jensen, Yves T. Wang, Simon Melov, Carolina N. Turk, Jason T. Matzen, Victoria J. Dardov, H. Michael Petrassi, Shelly L. Meeusen, Irina V. Perevoshchikova, Heinrich Jasper, Paul S. Brookes, Edward K. Ainscow
Journal: Cell Metabolism (2016)
Survival of<i>Mycobacterium abscessus</i>isolated from people with cystic fibrosis in artificially generated aerosols
Authors: Louise A. Fletcher, Yang Chen, Paul Whitaker, Miles Denton, Daniel G. Peckham, Ian J. Clifton
Journal: European Respiratory Journal (2016)

Non-tuberculous mycobacterium (NTM) are increasingly found in the sputum of people with cystic fibrosis (CF), both in Europe and North America [1]. Specifically, Mycobacterium abscessus has emerged as a potentially important pathogen, with evidence of accelerated lung function decline [2]. Studies from two CF centres have found evidence of cross-infection between individuals with CF [3, 4], whereas studies from other centres have not replicated this finding [5–7]. M. abscessus has been isolated from household water and has been previously isolated from shower aerosols of people with pulmonary NTM disease [8, 9]. M. abscessus survives aerosolisation suggesting airborne transmission between people with CF may occur <http://ow.ly/K2x6302JpAW>